Literature DB >> 19670218

The lily-of-the-valley fragrance receptor--potential in prostate cancer imaging.

Alexander Sturzu1, Hartmut Echner, Stefan Heckl.   

Abstract

BACKGROUND: The early diagnosis of prostate cancer and its metastases still remains a great challenge. Recently, olfactory receptors have been found in healthy and malignant prostate tissue. If conjugated to a dye, olfactory receptor ligands would represent candidates for markers of not only olfactory cells but also prostate tissue. Such a conjugate would be of great value for the detection of prostate cancer metastases.
METHODS: We coupled sulforhodamine, a fluorescence dye, to undecylic aldehyde, the antagonist of the lily-of-the-valley fragrance receptor. By using confocal laser scanning microscopy and flow cytometry we examined the uptake of this conjugate into various different human cell lines. One healthy prostate cell line, two different prostate carcinoma cell lines, and five other carcinoma cell lines were investigated. CD1 nude mice bearing human PC3 prostate carcinoma xenografts were injected with the conjugate. Rhodamine fluorescence of mouse organ frozen sections was evaluated by confocal laser scanning microscopy.
RESULTS: When comparing the seven human cell lines, the conjugate was preferentially taken up by the cytoplasm of healthy and malignant prostate cells. The mice showed high conjugate uptake into the xenografts, but much lower uptake into the mouse organs. After 3 hr of circulation, efflux could be observed in the xenograft sections. Xenograft touch prints confirmed in vivo intracellular accumulation.
CONCLUSION: This conjugate may be of potential value in the diagnosis of prostate cancer and its metastases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19670218     DOI: 10.1002/pros.21009

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  1 in total

1.  Novel bourgeonal fragrance conjugates for the detection of prostate cancer.

Authors:  Alexander Sturzu; Sumbla Sheikh; Hartmut Echner; Thomas Nägele; Martin Deeg; Christian Schwentner; Marius Horger; Ulrike Ernemann; Stefan Heckl
Journal:  Invest New Drugs       Date:  2013-03-19       Impact factor: 3.850

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.